Reddys and Glenmark are investing in novel therapies, from immuno-oncology to CNS
Dierks, C., Mmke, S., Philipp, U
Residents in Kentucky report that this makes healthier living feel much easier
This inventory build also suggests that Lilly expects substantial launch demand and wants to avoid the supply shortages that plagued the launches of Ozempic, Wegovy, and Mounjaro
Partnership activity across the obesity therapeutics market is increasingly driven by three factors: Manufacturing capacity for large-scale GLP-1 production Pipeline expansion through licensing and acquisitions New distribution models through digital health platforms Compounded GLP-1 prescriptions have attracted increased regulatory scrutiny in several markets as demand for obesity treatments continues to outpace supply
19% identified as Hispanic or Latino ethnicity